RTP Mobile Logo

Wednesday, May 16, 2018, Washington, DC, 6:00 PM – 8:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 1 — Lymphoma and Chronic Lymphocytic Leukemia

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:30 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Ethan M Basch, MD, MSc
Professor of Medicine and Public Health
Director, Cancer Outcomes Research Program
Co-Leader, Cancer Prevention and Control
Associate Chief, Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Amy Goodrich, CRNP-AC
Nurse Practitioner
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Robin Klebig, APRN, CNP, AOCNP
Division of Hematology, Lymphoma Group
Mayo Clinic
Rochester, Minnesota

Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director for Clinical Investigations
Division of Hematology and Oncology
GW Cancer Center
Washington, DC

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, and Seattle Genetics during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: Chronic Lymphocytic Leukemia (CLL)


  • Incidence of genetic abnormalities in CLL (eg, 17p deletions, TP53 and IGHV gene mutations) and implication for long-term prognosis
  • Selection of up-front treatment for CLL in younger and older patients with normal and high-risk cytogenetics
  • Integrating ibrutinib into the treatment algorithm for CLL: Activity and side-effect profile, including atrial fibrillation and risk of bleeding
  • Management of relapsed/refractory CLL: Incorporation of venetoclax for patients with del(17p) and potential role in non-del(17p) disease
  • Risk of and preemptive measures to prevent tumor lysis syndrome with venetoclax
  • Novel combination strategies currently under investigation

Module 2: Hodgkin Lymphoma (HL)


  • Relative benefits and risks of various combination chemotherapy regimens for newly diagnosed advanced-stage HL
  • Mechanism of action of brentuximab vedotin (BV) and role in the post-transplant consolidation and relapsed/refractory settings; potential incorporation into up-front treatment
  • Incidence and management of peripheral neuropathy and other toxicities associated with BV in HL
  • Biologic rationale for the efficacy of immune checkpoint inhibitors in HL and integration of nivolumab and pembrolizumab into the treatment algorithm for relapsed/refractory disease
  • Side effects and toxicities of anti-PD-1 antibodies; use in patients with prior autoimmune disorders
  • Use of nonchemotherapy approaches for elderly patients and those with comorbidities

Module 3: Follicular Lymphoma (FL)


  • Selection of treatment, including “watch and wait” and rituximab monotherapy, for patients with newly diagnosed FL
  • Comparative safety and efficacy of subcutaneous versus intravenous administration of rituximab in FL and other lymphomas
  • Integration of obinutuzumab-based induction and maintenance therapy for patients with previously untreated FL
  • Available research data and ongoing evaluation of rituximab/lenalidomide (R2)
  • Appropriate integration of copanlisib into current treatment algorithms; recognition, prevention and management of toxicities

Module 4: Diffuse Large B-Cell Lymphoma (DLBCL)


  • Molecular subtypes of DLBCL and impact on prognosis and potential treatment course
  • Management of relapsed/refractory disease, including the use of lenalidomide
  • Recent FDA approval and emerging clinical role of chimeric antigen receptor (CAR) T-cell therapy for patients with DLBCL and other aggressive lymphomas
  • Practical considerations in the administration of CAR T-cell therapy
  • Novel agents and strategies currently under investigation in relapsed/refractory DLBCL

Module 5: Mantle Cell Lymphoma (MCL)


  • Clinical considerations and disease-related factors in the determination to administer treatment versus observe off therapy in patients with newly diagnosed MCL
  • Selection of front-line and maintenance therapy for younger and older patients with newly diagnosed MCL
  • Sequencing of available treatment options for relapsed/refractory MCL: bortezomib, lenalidomide, ibrutinib, et cetera
  • Counseling patients receiving oral therapies regarding adherence
  • Mechanism of action and tolerability of the recently FDA-approved second-generation BTK inhibitor acalabrutinib

Module 6: T-Cell Lymphoma (TCL)


  • Up-front therapy for younger and older patients with TCL; role of autologous stem cell transplant
  • Recent FDA approval and available safety and efficacy data with BV for patients with CD30-positive TCL
  • Patient- and/or disease-specific factors guiding the sequence and selection of BV, pralatrexate and romidepsin in TCL

Special Session: Dr Basch

Using innovative communication strategies to assist nurses and other caregivers in meeting the needs of patients with cancer

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphoma and chronic lymphocytic leukemia (CLL).

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Provide patient-focused education to enhance clinical decision-making regarding available systemic agents used in the management of indolent and aggressive forms of B-cell non-Hodgkin lymphoma (NHL), including CLL, and Hodgkin lymphoma (HL).
  • Appreciate the contribution of patient performance status and comorbidities, biomarker profile and prior therapeutic exposure to the selection and sequence of systemic therapy for newly diagnosed and relapsed/refractory (R/R) CLL.
  • Review recent therapeutic advances in the management of newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and HL, and use this information to counsel patients regarding protocol and nonresearch options.
  • Formulate supportive care strategies to manage the side effects associated with recently approved therapeutic interventions for patients with HL, NHL and CLL.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 2.5 contact hours is provided by RTP.

This activity is awarded 2.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, and Seattle Genetics.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 1 — Lymphoma and Chronic Lymphocytic Leukemia. Onsite registration will be open starting at 5:15 PM (ET) on Wednesday, May 16th.

If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.